Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), Carpen
Edwards Lifesciences, LLC · Decision date Oct 28, 2026
What did the FDA decide?
This 30-day notice for supplement S228 to PMA P860057 states that the change is implementing an alternative supplier of a chemical manufacturing aid. The affected device is the Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), a replacement heart valve under product code DYE.
The notice does not describe the chemical manufacturing aid, the previous or alternative supplier, or any resulting process validation. It also does not state that safety or clinical effectiveness was independently demonstrated. The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier, and it does not constitute a new approval of the valve system.
FDA approval order statement
implementing an alternative supplier of a chemical manufacturing aid
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P860057/S228
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- DYE
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: replacement Heart-valve.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- DYE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P860057. Subsequent supplements may change the device or its indications.
FDA decision timeline
P860057 · Original PMA
EDWARDS LIFESCIENCES PERIMOUNT AORTIC AND MITRAL BIOPROSTHESES
P860057/S228 received
Application receipt date recorded by FDA.
P860057/S228 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P860057. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P860057
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Sep 26, 1991 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P860057/S228
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records